Device closure of muscular ventricular septal defects using the Amplatzer muscular ventricular septal defect occluder: Immediate and mid-term results of a U.S. registry

TL;DR: The peratrial device closure of PmVSDs is feasible, safe, and efficacious, compared with the perventricular technique, and has the advantages of less trauma, shorter hospital stays and procedure time, and better cosmetic results.

TL;DR: Percutaneous closure of complex VSDs is possible, safe and effective procedure in highly specialized centers and Appropriate patient selection is of paramount importance to the success of the procedure.

TL;DR: Device closure of VSD in presence of mild AVP and mild AR appears to be safe, but longer follow-up is necessary to draw final conclusion.

TL;DR: In this article, the authors report the case of a 79-year-old patient who developed an apical rupture of the ventricular septum, nine days after an anterior myocardial infarction.

TL;DR: It is suggested that ongoing spontaneous resolution of residual shunting occurs after device insertion, and factors related to the defect or device could not predict eventual resolution of remnant shunting.

TL;DR: Perventricular closure of multiple muscular ventricular septal defects is safe and effective and could become the treatment of choice for any infant with muscular Ventricle free wall defects or any child with muscular ventricle sePTal defect and associated cardiac defects.

TL;DR: This encouraging initial clinical success indicates that the AVSDO is a promising device for transcatheter closure of MVSDs in children, and further clinical trials and longer follow-up are needed before the widespread use of this technique can be recommended.

TL;DR: The Amplatzer MVSD occluder is a safe and effective device for closure of MVSDs up to 12 mm in diameter and further clinical trials with this device are underway.